MEDICAL

ILC Dover Announces Liquid Single-Use Bioprocessing Bags for Rapidly Growing Biotherapeutics and Cell & Gene Therapy Markets

ILC Dover | March 30, 2022

ILC_Dover_Announces
ILC Dover LP ("ILC Dover" or the "Company"), specializing in innovative single-use solutions for biotherapeutics and pharmaceutical processing, announced its launch of liquid single-use bioprocessing bags, representing the first of many new products for handling and supply of sterile liquids for the biotherapeutics market. This expansion is a continuation of ILC Dover's solution set across the entire biotherapeutic and pharmaceutical manufacturing workflow, from powder containment and handling, through sterile liquid handling and pre-filled liquid and powder bags.

ILC Dover manufactures its high-quality, single-use bioprocessing bags in Frederica DE, but ultimately will utilize its growing cGMP global footprint to support its customers and partners worldwide. The Company maintains manufacturing for its pharmaceutical and biotherapeutic customers in Frederica DE, Durham NC, Stockport UK, Rossens Switzerland, and Blarney Ireland, with a large, planned expansion in Juarez, Mexico coming online later in 2022.

ILC Dover's differentiated value proposition comes during a time of unprecedented disruption in the life science supply chain amidst significant industry growth. ILC Dover is committed to providing comprehensive solutions customized to our customers unique needs. Additionally, the Company's overall global footprint, quality, and supply reputation ensure that it can meet customer needs at scale with speed.

In addition to the launch of ILC Dover's single-use bioprocessing bags, the Company is also rapidly expanding its offering of sterile liquids and (pre-filled and non pre-filled) powder offerings. ILC Dover will be providing updates throughout the year on these launches.

In the past two weeks, we've made two large investments in our customers' success: our Juarez capacity expansion and transformation, and the official launch of our exciting single-use bioprocessing bags, We will continue to innovate to serve our pharmaceutical, biotherapeutic, and cell & gene therapy customers across the entire processing and manufacturing workflow."

Corey Walker, CEO of ILC Dover.

About ILC Dover
ILC Dover is a world-leader in the innovative design and production of solutions for biopharmaceutical, pharmaceutical, medical device markets as well as a leading supplier for the (aero)space industries. Our customers will attest to our relentless dedication to high value products, advanced technology, and responsive service, as our visionary solutions have improved efficiency while safeguarding people, product, and infrastructure in hazardous conditions through flexible protective solutions since 1947.

Spotlight

It’s been an interesting year for Biotech, as we repeatedly stress. But there are some biotechs which have been less robust against these tumultuous times, whilst others which have ‘made it big’.


Other News
MEDICAL

Anixa Biosciences Announces the Initiation of its Ovarian Cancer CAR-T Phase 1 Trial at Moffitt Cancer Center

Anixa | March 31, 2022

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced the initiation of a Phase 1 trial evaluating its novel chimeric antigen receptor T-cell (CAR-T) therapy in ovarian cancer. The CAR-T approach used for Anixa's therapy is known as chimeric endocrine receptor T-cell (CER-T) since the target of the engineered T-cells is an endocrine receptor. The Phase 1 trial at Moffitt Cancer Center will evaluate the safety and efficacy of Anixa's therapy in patients with ovarian cancer. Anixa holds an exclusive, worldwide license for the technology, which was developed at the Wistar Institute. While CAR-T therapy has shown efficacy in some hematological tumors, reproducing the same results with solid tumors, such as ovarian cancer, has proven challenging. One of the reasons for this difficulty is that effective CAR-T therapy needs a specific antigen to recognize that is only present on target cancer cells in order to avoid negatively affecting healthy cells. The CER-T therapy being evaluated in Anixa's Phase 1 study differs from traditional CAR-T in that it targets the follicle stimulating hormone receptor (FSHR), which research indicates is exclusively expressed on ovarian cells in healthy adult females. We are thrilled to have partnered with world-class scientists at Moffitt Cancer Center to advance our CER-T platform and feel that this partnership provides a critical opportunity to make a significant impact on the treatment of solid tumors, We strongly believe that our unique targeting approach differentiates our CER-T platform from traditional CAR-T approaches and that CER-T has potential to work in solid tumors where other therapies have failed." Dr. Amit Kumar, President, CEO and Chairman of Anixa Biosciences. CAR-T therapies are rapidly becoming an important player in cancer therapy, and our lab has developed a technology that has the potential to target tumors by using an existing biological mechanism that is well understood. If our CER-T approach is successful, it could serve as a model for future targeted CAR-T therapies in other cancer types. The goal in cancer therapy has always been to kill cancer cells with limited damage to healthy tissue, and we look forward to seeing how this CER-T therapy may be able to accomplish that in solid tumors, which have historically proven challenging to eradicate with cell therapy." Jose R. Conejo-Garcia, M.D., Ph.D., Chair of the Department of Immunology at Moffitt Cancer Center and co-inventor of the CER-T technology. About Anixa's CER-T Approach (Follicle Stimulating Hormone Receptor-Mediated CAR-T technology) Anixa's chimeric antigen receptor T-cell (CAR-T) technology approach is an autologous cell therapy comprised of engineered T-cells that target the follicle stimulating hormone receptor (FSHR). FSHR is found at immunologically relevant levels exclusively on the granulosa cells of the ovaries. Since the target is a hormone (chimeric endocrine) receptor, and the target-binding domain is derived from its natural ligand, this technology is known as CER-T (chimeric endocrine receptor T-cell) therapy, a new type of CAR-T. About Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company with a number of programs addressing cancer and infectious disease. Anixa's portfolio of therapeutics includes a cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and, with partner MolGenie GmbH, a COVID-19 program focused on compounds targeting the Mpro enzyme of SARS-CoV-2, which is largely conserved across all recently identified variants like Delta and Omicron. The company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple negative breast cancer (TNBC), the most lethal form of the disease – as well as a vaccine to prevent ovarian cancer. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on clinical development allows the company to continually examine emerging technologies in complementary fields for further development and commercialization

Read More

INDUSTRIAL IMPACT

WILLOW BIOSCIENCES TO HOST INVESTOR PRESENTATION WEBCAST

Willow Biosciences Inc. | February 01, 2022

Willow Biosciences Inc. a leading biotechnology company that manufactures pure, consistent and sustainable cannabinoids via yeast biosynthesis, announced that it will host a webcast investor presentation on Thursday, February 3rd at 2:00 PM EST. During the webcast, Willow's President and Chief Executive Officer Trevor Peters will provide a presentation through a PowerPoint discussion that will cover key areas of Willow's business. After the formal presentation, investors will have an opportunity to ask relevant questions through an interactive Q&A portal. About Willow Biosciences Inc. Willow is a leading biotechnology company that develops and produces high-purity, plant derived ingredients for the consumer care, food and beverage, and pharmaceutical markets. Willow's FutureGrown™ biotechnology platform allows scale production of pure, consistent, and sustainable product to benefit both B2B and B2C customers. Willow's R&D team has a proven track record of developing and commercializing bio-based manufacturing processes and products for both the consumer and pharmaceutical industries.

Read More

MEDICAL

Ambagon Therapeutics Launches With $85 Million Series A to Advance Pioneering Molecular Glue Platform and Progress Pipeline

Ambagon Therapeutics | January 07, 2022

Ambagon Therapeutics, a biotechnology company unlocking intrinsically disordered proteins and other difficult-to-target protein classes, announced an $85 million Series A to augment its drug discovery platform and to advance its pipeline of molecular glues. The financing was led by Nextech Invest. Ambagon was previously seeded by RA Capital Management, Droia Ventures, Inkef Capital, AbbVie Ventures, MRL Ventures Fund, and Mission BioCapital. Investors from the seed round joined the A round, along with new investor Surveyor Capital. Many disease-relevant proteins have regions of intrinsic disorder that cannot be targeted by conventional small molecule drugs. Several thousand proteins with such intrinsically disordered regions have been identified that interact with the hub protein 14-3-3. In binding to a disordered protein region, 14-3-3 induces order, conferring druggability. By stabilizing naturally occurring 14-3-3:client interactions, Ambagon aims to rapidly develop novel therapeutic candidates for difficult-to-drug proteins. The pipeline currently focuses on oncology, where many opportunities exist to engage currently-undruggable targets. Ambagon was founded by world leaders in 14-3-3 biology and drugging protein-protein interactions: Michelle Arkin, Professor and Chair of Pharmaceutical Chemistry and co-Director of the Small Molecule Discovery Center at UCSF, Luc Brunsveld, Professor of Chemical Biology at the Eindhoven University of Technology (TU/e), and Ambagon Chief Technology Officer Christian Ottmann, Associate Professor of Molecular Cell and Structural Biology, TU/e. Ambagon’s seasoned leadership team includes Chief Executive Officer Scott Clarke, previously CEO of Tizona Therapeutics and Trishula Therapeutics, and Chief Scientific Officer Nancy Pryer, previously CSO at Day One Biopharmaceuticals and Chief Development Officer at Nurix Therapeutics. “Our deep understanding of 14-3-3 biology has broad applications for drug discovery as it opens up disordered protein regions as therapeutic targets. Combined with our proprietary structural insights, curated chemical library, and bespoke drug discovery tools, our experienced drug development team is well placed to bring forward new medicines addressing previously undruggable targets.” Scott Clarke “Ambagon’s modular approach for leveraging 14-3-3 biology to enable drug discovery is not just unique, but uniquely well-conceived,” said Melissa McCracken, Partner, Nextech Invest. “We are excited to see such an exciting platform translate into a very rich pipeline.” “We are proud to continue to support Ambagon as it works to create first-in-class and best-in-class drugs through targeted stabilization of protein complexes,” said Adam Rosenberg, Ambagon’s Chair and RA Capital Venture Partner. “Since our seed investment, the team has developed an impressive proprietary dataset and systemic understanding of 14-3-3 interactions. Ambagon truly has the potential to change the narrative for disordered targets.” About Ambagon Therapeutics Ambagon Therapeutics is a biotechnology company pioneering methods to unlock intrinsically disordered protein targets using small molecules. Ambagon applies deep knowledge of 14-3-3 proteins and a proprietary suite of drug discovery tools to create molecular glues that stabilize 14-3-3:target complexes. These molecular glue stabilizers amplify native biology to restore or inhibit target function, potentiate target activity, or promote or block target degradation. Ambagon’s initial focus is on oncology, with five programs in discovery. It has locations in San Carlos, California, and Eindhoven, the Netherlands. About 14-3-3 Biology Ambagon’s platform harnesses the biology of the regulatory hub protein 14-3-3, which reads serine/threonine phosphorylation. With more than 3000 client proteins reported, 14-3-3 has a vast interactome, enabling the manipulation of a broad range of biology across indications. In binding its clients, 14-3-3 imposes order on disordered client protein sequences, conferring druggability on otherwise undruggable proteins and protein regions. About the Modular Ambagon Drug Discovery Platform By selectively stabilizing the interaction between 14-3-3 and a 14-3-3 client protein, Ambagon can create first-in-class drugs addressing high value targets inaccessible by other means, particularly those with a high degree of disorder, including transcription factors, adaptor/scaffolding proteins, and RNA binding proteins.

Read More

INDUSTRIAL IMPACT

c-LEcta Announces That It Has Reached Agreement to Be Acquired by Kerry Group

c-LEcta | February 16, 2022

c-LEcta, a leading biotechnology company in enzyme engineering and bioprocess development, has announced that it has reached an agreement with Kerry Group for it to acquire a majority shareholding of the company. Kerry is a world-leading taste and nutrition partner for the food, beverage, and pharmaceutical markets. This strategically compelling combination will accelerate Kerry’s innovation capabilities in enzyme engineering, fermentation and bio-process development while also enabling c-LEcta to fufill its long term growth potential. “We are very happy to join Kerry group and their global presence in the food and pharmaceutical sectors gives us access to additional markets. At the same time, their expertise in ingredient technologies and applications is a perfect fit as we continue to drive our growth potential in the future. We will continue to collaborate with our existing industry partners and will of course continue to produce and distribute our products for our valued customers.” Dr Marc Struhalla, founder and CEO of c-LEcta Thomas Pfaadt, CFO of c-LEcta adds: “We want to thank our previous investors for the great cooperation over the past years. Without their contribution, such a development would not have been possible. Together, we have achieved a lot and we are thankful for their support.” Commenting on the agreement with c-LEcta, Dr Albert McQuaid, Chief Science and Technology Officer of Kerry, said: “The food and pharmaceutical industries are on the cusp of a new wave of innovation where new developments in biotechnology, synthetic biology and precision fermentation are radically transforming these sectors. c-LEcta is a leader in these new technologies, which includes fermentation-based products such as disruptive new enzymes, and the strategically compelling combination with Kerry will accelerate our innovation capabilities in enzyme engineering, fermentation and bio-process development. Our broad market reach across food and pharma markets, combined with our deep enzyme applications expertise and integrated ingredient technology design, will enable and accelerate the growth potential of c-LEcta’s strong portfolio and technology capabilities while also supporting us in the creation of tastier, more sustainable and healthier products.” About c-LEcta c-LEcta is a leading biotechnology company located in Leipzig, Germany. The company has established itself as a leading player in the realisation of high-value biotechnology products for regulated markets, either as in-house development or in close cooperation with the industry. c-LEcta innovation capability delivers cost-efficient and sustainable production processes, creating growth opportunities across existing and new markets. About the Kerry Group Kerry is a world-leading taste and nutrition partner for the food, beverage, and pharmaceutical markets and with its broad portfolio of ingredient solutions reaches more than one billion customers worldwide. Together with their customers, Kerry develops innovative products with great taste, improved nutritional value, and higher functionality, while having a better impact on the environment. Thanks to their leading consumer knowledge, their global RD&A team with more than 1,100 food scientists, and their comprehensive, global presence, Kerry can overcome the complex challenges of their customers with differentiated solutions. Kerry is willing to be a valued partner for their customers and to create a world of sustainable nutrition.

Read More